Altered CD44 expression, including the presence of specific alternative isoforms (e.g., CD44v6), correlates with increased tumor aggressiveness and a poorer clinical prognosis in numerous types of cancer, including colon, breast, and gastric cancers, as well as leukemias. This evidence concerns the gene CD44 and cancer.